Breast Cancer Diagnosis Costs Higher in the U.S. than Europe: Market Led by C. R. Bard and Hologic
With just under 60% of the amount spent in the U.S., European health authorities bought close to 500,000 more biopsy needles for breast cancer treatment and prevention.
VANCOUVER, July 21, 2014 /PRNewswire/ - According to breast cancer biopsy market data released by iData Research (www.idataresearch.com), the European health authorities brought almost 500,000 more biopsy needles in 2013. Notably, the U.S. market focuses more on expensive minimally invasive technologies. European healthcare clearly favors cost-effective breast cancer technology, purchasing significantly greater volumes due in part to national breast screening programs.
"Europe sees more than four times the purchases of inexpensive SLC (spring-loaded core) needles than the United States," explains Dr. Zamanian, CEO of iData. "And this is done at a fraction of the cost." The same needle to diagnose and treat breast cancer in the United States can be more than 70% cheaper in Europe.
Other key information in iData's analysis of the U.S. and European Breast Biopsy Device Markets include:
- At-Risk Women over 40: In both the U.S. and Europe, aging demographics are driving the purchase of breast cancer treatment and diagnosis technology. Most breast cancer diagnoses occur after a woman reaches the age of 40.
- New Minimally Invasive Technologies in the U.S.: Minimally invasive vacuum-assisted breast biopsy (VABB) devices in the United States receive considerably more attention, with notably more unit sales and a market value nearly twice as large as that of Europe. With the added focus, the U.S. has visible markets for new technologies that use stereotactic x-ray guidance, ultrasound, as well as magnetic resonance and molecular imaging guidance techniques.
- Growing U.S. Market Value: Moving towards 2019, the European market for breast cancer needles is projected to grow by just over $10 million. Comparatively, the U.S. market is projected to grow by almost $33 million. Average product prices will stay relatively stable overall for both markets. Greater numbers of unit sales are anticipated in the U.S., but will be roughly comparable to European unit sales numbers. The greater U.S. market value will be derived by higher prices.
Hologic led the U.S. breast cancer needle market with their minimally invasive VABB needle products. C. R. Bard dominated the less expensive U.S. core needle market, and also held a commanding presence in Europe in this same market. Hologic still struggles to gain significant breast biopsy device traction in Europe, with most of their breast biopsy device revenue coming from the United States. Other U.S. and European competitors include Devicor, Intact Medical, Mammotome, Argon Medical and Carefusion.
For Further Information
The Global Breast Biopsy Devices report is part of the complete Women's Health Market series and is available for the U.S., Japan, South Korea, Australia and 15 countries in Europe. These reports provide a comprehensive analysis including units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players' success strategies in each market and segment. The Global Breast Biopsy Devices report includes Spring-Loaded Core Needle, Vacuum-Assisted and Rotational Cutting Device, Stereotactic X-Ray Guided Biopsy, Ultrasound Image Guided Biopsy.
About iData Research
iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.
SOURCE iData Research Inc.